WATERBURY, CT, Feb. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Marathon Group Corp. (OTC: PDPR) (the “Company” or
“Marathon”) is pleased to announce our subsidiary, MarathonRx, has secured their first product, 1,500mg Nano-Pure Ultra CBD Drops
via a signed agreement with a well-respected NY based cannabinoid specialty company.
Nano-Pure Ultra CBD Drops are a fast absorbing sublingual method of CBD delivery. These drops are made with pure hemp extract,
along with other natural ingredients, to increase absorption for fast acting relief. Our cannabinoid delivery system increases the
CBD delivery by over 450%, compared to hemp on its own, due to our extremely small CBD particle size.
The market for Hemp CBD oil is set to explode over the next few years. As discussed in our recent press release, the size of the
hemp CBD consumer market alone is projected to reach $22 billion dollars per year in sales by 2022 (Brightfield Group).
As a result of recent consumer and industrial pressure, the US has passed the Farm Bill, easing federal restrictions on hemp
production. This will allow an increase in production and a subsequent decrease in costs, increasing the market potential to a
larger portion of the population. A TechNavio report (https://www.technavio.com/report/global-cbd-oil-market-analysis-share-2018) indicates the CBD
oil market is expected to grow by 31% year over year through 2022.
Ongoing scientific research into the uses of CBD oil for pain, anxiety/depression, cancer related symptoms, acne,
neuroprotective properties, heart health, diabetes, anti-inflammatory properties and many more. A search on https://www.ncbi.nlm.nih.gov/pubmed/?term=cbd+oil for the term 'CBD oil' brings up a number of
studies regarding the widespread benefits of CBD oil use.
In addition to our new flagship product, MarathonRx is preparing to launch an online web portal for direct retail purchasing of
all our products. Our initial agreement includes supply of Hemp extract oils, Pain care and skin care product lines, will be
expanding to encompass additional products. Further details will be released in the near future.
“Our mission is to deliver the highest quality products and services to the CBD wellness industry. With our new 1,500 mg/oz
Nano-Pure Ultra CBD Drops, we are providing the highest quality and speed of absorption available, meeting that mission,” commented
MacDonald Tudeme, President and CEO of Marathon.
You can stay up to date with our progress by visiting our website http://www.marathonrx.com and subscribing to our newsletter.
About MarathonRx, Inc.
MarathonRx is a wholly owned subsidiary of Marathon Group Corp. (OTC: PDPR), formed to explore the various opportunities that
are available in the booming legal cannabis industry. As the regulatory landscape continues to evolve for cannabis products
and services, MarathonRx will leverage its parent company’s proven expertise in point-of-sale solutions, digital marketing,
e-commerce, advertising and lead generation.
About Marathon Group Corp
Marathon Group Corp. (PDPR) is a Connecticut-based software company engaged in web property development, focused on solving
problems faced by small and medium size businesses.
Safe Harbor Statement
The matters discussed, particularly information regarding future revenue, earnings, business plans and goals, consist of
forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 and are subject to the safe harbor created by these sections and involve risks and uncertainties, which could
cause actual results to differ materially from the forward-looking information. Such statements are not guarantees of future
performance and involve risks, uncertainties and assumptions that are difficult to predict. These statements are based on
assumptions and estimates that management believes are reasonable based on currently available information; however, management’s
assumptions and the Company’s future performance are both subject to a wide range of business risks and uncertainties, and there is
no assurance that these goals and projections can or will be met. Any number of factors could cause actual results to differ
materially. The Company undertakes no obligation to publicly update or revise any forward-looking statements. All forward-looking
information contained herein is subject to the risk factors and uncertainties described in the Company’s filings with the
Securities and Exchange Commission, which risk factors and uncertainties are incorporated by reference as though fully set forth
herein.
Contact: MacDonald Tudeme jasmactt@gmail.com Investor Relations: Rage Marketing Inc. info@ragemarketinginc.com (800) 867-1851
